FIZE Medical Raises $20 Million in Series B to Advance AI-Guided ICU Care

The funding will support the development of FIZE Optima the company’s next generation platform for AI-guided fluid management in intensive care units (ICUs). Asahi Kasei Medical which is already FIZE Medical’s exclusive distributor in Japan will also distribute FIZE kUO in Europe.

The round follows a $14 million funding round raised two years ago. FIZE Medical had raised $30 million before the Series B, bringing its total funding to $50 million if the company reaches the full $20 million financing target.

What is FIZE Medical?

FIZE Medical is an Israeli medtech company focused on fluid management for critically ill patients. Its FIZE kUO system provides real time digital monitoring of urine output, helping healthcare teams monitor kidney function manage fluid levels and identify risks earlier.

The company is also developing FIZE Optima, a next generation platform that uses continuous physiological data and AI to predict fluid related risks and support clinical treatment decisions.

FIZE kUO is commercially available in Japan, Europe and the U.S. In Israel, the system is being used across 60 intensive care beds at hospitals including Soroka and Beilinson. Sheba is also expected to implement the system.

Funding Details

FIZE Medical's latest financing is a Series B round targeting $20 million. The first close was co-led by Asahi Kasei Medical and Rapha Capital Management.

The funding comes two years after the company's previous $14 million raise. FIZE Medical had raised $30 million before the latest round. If the full Series B target is completed, the company will have raised $50 million in total.

The round also expands FIZE Medical's relationship with Asahi Kasei Medical. The Japanese company already serves as FIZE Medical's exclusive distributor in Japan and will now distribute FIZE kUO in Europe.

How Will FIZE Medical Use the Funding?

FIZE Medical will use the new funding to accelerate development of FIZE Optima and its AI-driven prediction and treatment guidance capabilities.

The company will also use the capital to strengthen its commercial activities in its leading markets and support its expansion into Europe.

Company Background

FIZE Medical began operations in 2019, while the initial development of its technology started in 2011 under the leadership of Noam Levine.

The company is currently led by Dror Zerem, who has previously served as CEO of companies including Ophir Optronics and VisionMap. VisionMap was acquired by Rafael.

FIZE Medical currently employs around 40 people. Its technology focuses on improving how fluid balance and kidney function are monitored in critically ill patients.

Market and Business Growth

FIZE Medical is expanding its commercial presence through its partnership with Asahi Kasei Medical. After launching FIZE kUO in Japan, Asahi Kasei Medical will now distribute the system in Europe.

The company is also advancing FIZE Optima, which is designed to move beyond monitoring urine output toward predicting fluid-related risks using continuous patient data.

What Happens Next?

FIZE Medical will focus on developing FIZE Optima and expanding its commercial activities across key markets. The company will also work with Asahi Kasei Medical to expand access to FIZE kUO in Europe.

Leadership Statements

"Asahi Kasei Medical has been an important and trusted partner in bringing FIZE kUO to clinicians in Japan, and this investment represents a meaningful next step in our relationship," said Dror Zerem, CEO of FIZE Medical. "We are moving beyond monitoring toward a future in which continuous patient data can help clinicians anticipate fluid-related risk and make more informed treatment decisions. Having Asahi Kasei Medical deepen its commitment to FIZE at this stage is a powerful validation of both our technology and vision."

"As a world leader in development and production of devices and systems for blood treatment and purification, we already know this space well, and fluid management is a natural extension of our presence in critical care," said Shuichiro Inadome, CEO of Asahi Kasei Medical. "We're excited to deepen our partnership with FIZE Medical as it advances from precision monitoring toward predictive, AI-powered fluid management. We see significant potential in FIZE's technology and look forward to expanding access to FIZE kUO in Europe."

"Asahi Kasei Medical's investment is a vote of confidence in FIZE Medical's technology and trajectory," said Kevin Slawin, M.D., Founder and Managing Partner of Rapha Capital Management. "We began investing in FIZE from its earliest stage because we believed in its potential to fundamentally change medicine through its groundbreaking kUO device. Today, we continue that commitment as FIZE establishes the kUO as the leading device in real-time kidney urine output data collection and takes the next step towards utilizing that data to deliver real-time fluid management solutions to clinicians when it's needed most."

Read Also - MIND Security Raises $72 Million in Series B to Expand DLP Platform